

## A novel human immunoglobulin Fc $\gamma$ -Fc $\epsilon$ bifunctional fusion protein inhibits Fc $\epsilon$ RI-mediated degranulation

By: Daocheng Zhu, [Christopher L. Kepley](#), Min Zhang, Ke Zhang, and Andrew Saxon

Zhu D, Kepley, CL, Zhang M, Zhang K, Saxon A. A novel human immunoglobulin Fc $\gamma$ -Fc $\epsilon$  bifunctional fusion protein inhibits Fc $\epsilon$ RI-mediated degranulation. *Nature Medicine*, 2002; 8:518-21.

Made available courtesy of Nature Publishing Group: <https://doi.org/10.1038/nm0502-518>

\*\*\*© 2002 Nature Publishing Group. Reprinted with permission. No further reproduction is authorized without written permission from Nature Publishing Group. This version of the document is not the version of record. Figures and/or pictures may be missing from this format of the document. \*\*\*

### Abstract:

Human mast cells and basophils that express the high-affinity immunoglobulin E (IgE) receptor, Fc $\epsilon$  receptor 1 (Fc $\epsilon$ RI), have key roles in allergic diseases. Fc $\epsilon$ RI cross-linking stimulates the release of allergic mediators<sup>1</sup>. Mast cells and basophils co-express Fc $\gamma$ RIIb, a low affinity receptor containing an immunoreceptor tyrosine-based inhibitory motif and whose co-aggregation with Fc $\epsilon$ RI can block Fc $\epsilon$ RI-mediated reactivity<sup>2,3,4</sup>. Here we designed, expressed and tested the human basophil and mast-cell inhibitory function of a novel chimeric fusion protein, whose structure is  $\gamma$ Hinge-CH $\gamma$ 2-CH $\gamma$ 3-15aa linker-CH $\epsilon$ 2-CH $\epsilon$ 3-CH $\epsilon$ 4. This Fc $\gamma$ -Fc $\epsilon$  fusion protein was expressed as the predicted 140-kD dimer that reacted with anti-human  $\epsilon$ - and  $\gamma$ -chain specific antibodies. Fc $\gamma$ -Fc $\epsilon$  bound to both human Fc $\epsilon$ RI and Fc $\gamma$ RII. It also showed dose- and time-dependent inhibition of antigen-driven IgE-mediated histamine release from fresh human basophils sensitized with IgE directed against NIP (4-hydroxy-3-iodo-5-nitrophenylacetyl). This was associated with altered Syk signaling. The fusion protein also showed increased inhibition of human anti-NP (4-hydroxy-3-nitrophenylacetyl) and anti-dansyl IgE-mediated passive cutaneous anaphylaxis in transgenic mice expressing human Fc $\epsilon$ RI $\alpha$ . Our results show that this chimeric protein is able to form complexes with both Fc $\epsilon$ RI and Fc $\gamma$ RII, and inhibit mast-cell and basophil function. This approach, using a Fc $\gamma$ -Fc $\epsilon$  fusion protein to co-aggregate Fc $\epsilon$ RI with a receptor containing an immunoreceptor tyrosine-based inhibition motif, has therapeutic potential in IgE- and Fc $\epsilon$ RI-mediated diseases.

**Keywords:** mast cells | human basophils | allergy | Fc receptors | histamine release

### Article:

Allergen aggregation of IgE bound to Fc $\epsilon$ RI induces release of preformed mediators and synthesis of later acting leukotrienes and chemokines from mast cells and basophils<sup>5</sup>. This process has a major role in many of human diseases such as asthma, allergic rhinitis, chronic urticaria, angioedema and anaphylaxis. Fc $\epsilon$ RI aggregation induces release of preformed mediators and synthesis of later-acting leukotrienes, chemokines and cytokines<sup>5</sup>. The Fc $\epsilon$ RI is a


heterotetramer consisting of a single IgE-binding  $\alpha$ -subunit, a  $\beta$ -subunit and two disulfide-linked  $\gamma$ -subunits. The  $\beta$ - and  $\gamma$ -subunit cytoplasmic tails each contain a conserved immunoreceptor tyrosine-based activation motif (ITAM). Cross-linking Fc $\epsilon$ RI via IgE bound to multivalent antigen activates tyrosine phosphorylation of ITAMs, thereby initiating downstream signaling<sup>6</sup>. Mast cells and basophils co-express Fc $\gamma$ RIIb, which contains two extracellular immunoglobulin-like loops and a single conserved immunoreceptor tyrosine-based inhibition motif (ITIM) within its cytoplasmic tail<sup>7</sup>. Fc $\gamma$ RIIb may co-aggregate with Fc $\epsilon$ RI under physiologic conditions. It is hypothesized that when Fc $\gamma$ RIIb aggregates, it induces inhibitory signaling via SH2-domain-containing inositol 5-phosphatase (SHIP) and phosphorylation of Fc $\gamma$ RIIb requires the co-aggregation with Fc $\epsilon$ RI (refs. 8,9). Aggregating Fc $\gamma$ RII to Fc $\epsilon$ RI leads to the rapid tyrosine phosphorylation of the Fc $\gamma$ RIIb ITIM tyrosine by Fc $\epsilon$ RI-associated Lyn and inhibition of Fc $\epsilon$ RI signaling<sup>10,11,12,13</sup>. To take advantage of this Fc $\gamma$ RIIb-negative signaling in human basophils and mast cells, we constructed a single chimeric human bifunctional protein (GE2) engineered by fusing the human Fc $\gamma$ 1 and Fc $\epsilon$ . Here we show that this chimeric protein is able to inhibit IgE-mediated *in vitro* activation of human basophils and mast cells and *in vivo* activation of human Fc $\epsilon$ RI $\alpha$ -bearing mast cells in Fc $\epsilon$ RI $\alpha$  transgenic mice. This approach using chimeric Fc $\gamma$  proteins provides a platform for non-specific as well as future antigen-specific inhibition of IgE–Fc $\epsilon$ RI-mediated reactivity in a host of human diseases.

Human genomic DNA encoding the IgG  $\gamma$ 1 constant region extends from the hinge through the CH3 domain. This sequence was initially cloned into a mammalian expression vector with a cytomegalovirus promoter and a murine immunoglobulin  $\kappa$ -chain leader sequence. Genomic DNA of the human  $\epsilon$  heavy chain CH2 through CH4 domains was placed after the CH $\gamma$ 3. Between Fc $\gamma$ 1 and Fc $\epsilon$ , we placed a 15 amino-acid linker (Gly<sub>4</sub>Ser)<sub>3</sub>, which has been used in single-chain Fv fragment expression<sup>14</sup>. This flexible peptide linker facilitates chain pairing and minimizes refolding and aggregation problems encountered when the two chains are expressed individually. The fusion protein contained the binding sites for Fc $\epsilon$ RI (CH $\epsilon$ 2–CH $\epsilon$ 3) and for Fc $\gamma$ RII (CH $\gamma$ 2–CH $\gamma$ 3)<sup>15,16</sup>. The first constant region domains (CH $\gamma$ 1 or CH $\epsilon$ 1) were deleted as this domain associates with BiP (immunoglobulin heavy-chain binding protein) and a fusion protein containing these regions was not expressed<sup>17</sup>. SDS–PAGE demonstrated the Fc $\gamma$ 1–Fc $\epsilon$  fusion protein was expressed as the predicted ~140-kD dimer. Western-blot analysis and ELISA testing demonstrated that the GE2 protein was recognized by antibodies specific for human  $\epsilon$  and  $\gamma$  chains.

Binding of GE2 to both the human Fc $\epsilon$ RI and Fc $\gamma$ RII was demonstrated using CHO3D10, a human Fc $\epsilon$ RI $\alpha$ -transfected cell line and HMC-1, which expresses human Fc $\gamma$ RII but not Fc $\epsilon$ R (ref. 18). GE2 protein bound to both Fc $\epsilon$ RI and Fc $\gamma$ RII in a fashion equivalent to human IgE and IgG, respectively, as assessed by flow cytometry (data not shown). These results demonstrate that expressed GE2 protein is properly folded so as to preserve bifunctional heterotypic FcR binding.


Fresh human basophils expressing both Fc $\epsilon$ RI and Fc $\gamma$ RII can be passively sensitized with chimeric human IgE specific for NIP (4-hydroxy-3-iodo-5-nitrophenylacetyl) and then histamine release induced by cross-linking the anti-NIP IgE–Fc $\epsilon$ RI complex with NIP-BSA (ref. 19). We sensitized basophils with 1  $\mu$ g/ml human anti-NIP IgE, plus doses of GE2 ranging from 0.01 to 10  $\mu$ g/ml for 1 hour before activation with 50 ng/ml NIP-BSA (Fig. 1a). Myeloma IgE (PS

myeloma) was used as a control. We found that 1  $\mu\text{g}$  GE2 at 1  $\mu\text{g}$  per ml inhibited almost half of histamine release, whereas at 10  $\mu\text{g}/\text{ml}$  GE2 gave an average of 84% inhibition. 10  $\mu\text{g}$  of non-specific PS IgE only decreased histamine release by 19%. Adding the GE2 at the same time as the IgE anti-NIP gave optimal inhibition. The longer the delay in GE2 addition following sensitization with IgE anti-NIP, the less the inhibition (Fig. 1b). These results show that the inhibition of antigen-driven histamine release induced by GE2 is dependent on time and dosage. We obtained similar results with cultured human mast cells; a dose of 1  $\mu\text{g}$  caused 50% inhibition of IgE-mediated degranulation (data not shown). Cross-linking of GE2 by adding an anti-IgG antibody *in vitro* along with GE2 caused enhanced inhibition of IgE-mediated release (data not shown). In performing this experiment, we sought to mimic what may occur *in vivo* should subjects given GE2 make an antibody response against it. The actual fate of antibody bound GE2, should it occur *in vivo*, is not possible to predict.



**Figure 1:** Dose- and time- dependent inhibition of basophil histamine release using GE2. **a**, Dose-dependence. Results are representative of 3 separate donors, each done in duplicate. **b**, Time-dependence. Results are representative of 2 separate donors, each done in duplicate. For both panels: \*, significant differences in histamine release ( $P > 0.05$ ), comparing the two indicated conditions. Total histamine in the donor basophils was 1.2  $\mu\text{g}$  per  $1 \times 10^6$  basophils.

Tyrosine phosphorylation of Syk is a critical step in human mast cell and basophil mediator release<sup>19</sup>. Cross-linking FcεRI on human basophils with IgE directed to NIP and NIP-BSA induces substantial tyrosine phosphorylation of Syk which was markedly reduced in cells pre-incubated with GE2 (Fig. 2). Thus, GE2 co-aggregation of FcεRI and FcγRII inhibits IgE-mediated Syk phosphorylation, which may contribute to the inhibition of histamine release.




**Figure 2:** Co-aggregation of FcγRII and FcεRI by GE2 inhibits FcεRI-mediated Syk phosphorylation. Immunoprecipitates were analyzed by western blotting with antibody against phosphotyrosine (top row), followed by anti-Syk antibody (bottom row). The top row represents phosphorylated Syk and the bottom row represents total Syk. Each lane shows Syk immunoprecipitated from  $5 \times 10^6$  basophils. Results represent 2 separate experiments.

Transgenic mice altered to express the human FcεRIα and with the murine FcεRIα chain knocked out demonstrate allergic reactivity mediated by passively administered human IgE antibody along with antigen<sup>20,21</sup>. The human FcεRIα chain is coupled with the mouse β and γ chains to form a functional chimeric human/mouse FcεRI. This model takes advantage of the fact that murine mast cells also express FcγRIIb that can interact well with human IgG. This is in contrast to the lack of interaction between the murine FcεRI and human IgE. We used passive cutaneous anaphylaxis (PCA) to test the GE2 protein's ability to block IgE-driven FcεRI-mediated mast-cell release. We intradermally primed transgenic mice with 250 ng of chimeric human anti-NP (4-hydroxy-3-nitrophenylacetyl) IgE and simultaneously injected individual sites with saline, GE2 or IgE myeloma protein. Four hours later, mice were given a systemic challenge with 0.5 mg NP-BSA plus 1% Evans Blue intravenously. The intensity of the PCA at each site was assessed by the size of the skin bluing after 30 min. The size and color intensity of the reaction at the sites of GE2 injection were decreased compared with sites injected with an equivalent amount of human IgE myeloma (Fig. 3). Similar results were obtained using genetically engineered human IgE anti-dansyl antibody and dansyl-BSA as an antigen. A total of 30 mice were tested and the GE2 was 2–4 times more potent than purified control human IgE in its ability to block PCA.

Our results demonstrate that a single chimeric molecular human protein consisting of Fcγ1 plus Fcε directly inhibits *in vitro* histamine release from human basophils and also inhibits humanized FcεRI-mediated mast-cell degranulation in transgenic mice. GE2 was more potent than control human IgE in all assays. Even if the GE2 protein did not have a 15 amino-acid linker between the two segments of 'normal' human Fcγ1 and Fcε, it would likely be recognized as foreign and induce an antibody response. With the 15 amino-acid linker, it is highly likely that antibody against GE2 would be expressed and will be primarily directed at this linker region. In fact, such an antibody response to GE2 may well prove advantageous as antibodies against GE2 will lead

to increased cross-linking of Fc $\gamma$  and Fc $\epsilon$  receptors and should enhance inhibition of basophil and mast-cell function as we have observed *in vitro* using an anti-IgG antibody. This truncated Fc $\gamma$ -Fc $\epsilon$  fusion protein, GE2, provides a novel approach for the immunotherapy of diseases mediated via the Fc $\epsilon$ R such as allergic asthma, allergic rhinitis, chronic urticaria, angioedema and anaphylaxis. Replacement of the Fc $\epsilon$  sequence in our construct with specific allergen genes will result in chimeric bifunctional proteins. We predict that these proteins will have the ability to inhibit mast-cell and basophil reactivity in an antigen-specific manner rather than in the global fashion of GE2. Such novel antigen-specific reagents may be useful in allergen immunotherapy.



**Figure 3:** *In vivo* immunoglobulin Fc $\gamma$ -Fc $\epsilon$  fusion protein inhibits IgE-mediated degranulation in transgenic mice. *a-d*, Mice were injected intradermally with the following: *a*, anti-NP IgE; *b*, saline; *c*, anti-NP IgE and GE2; *d*, anti-NP IgE and IgE myeloma.

## Methods

**Construction and expression.** To construct the human Fc $\gamma$ -Fc $\epsilon$  chimeric gene, the human IgE Fc region (CH2-CH3-CH4) was amplified from pAG vector (provided by S.L. Morrison), containing the whole e genomic DNA. The 5' end primer was 5'-GCTCGAGGGTGGAGGCGGTTTCAGGCGGAGGTGG CTCTGGCGGTGGCGGATCGTTCA CCCC GCCACCGTGAAG-3', containing a flexible linker sequence and a *Xho*I site. The 3' end primer was 5'-GGCGGCCGCTCATTTACCGGGATTTACAGACAC-3', containing a *Not*I site. After amplification, PCR products were cloned into pCR2.1 vector (Invitrogen, Carlsbad, California) and sequenced. Then the *Xho*I-*Not*I fragment was inserted into *Sal*I-*Not*I site of pAN expression vector (from S.L. Morrison), containing the human genomic IgG  $\gamma^1$  constant region from hinge through the end of CH3. The IgE Fc region was placed downstream of the IgG  $\gamma^1$  constant region in frame with the CH3 and joined by a (Gly<sub>4</sub>Ser)<sub>3</sub> flexible linker. The

expression vector containing the immunoglobulin Fc $\gamma$ -Fc $\epsilon$  chimeric gene was transfected into SP2/0 cells. The Fc $\gamma$ -Fc $\epsilon$  fusion protein GE2 was expressed in cell-culture supernatants and purified by using an anti-human IgE affinity column.

**Western-blot analysis.** The purified GE2 protein was run on 7.5% SDS-PAGE and then transferred into Immobilon transfer membranes (Millipore, Bedford, Massachusetts). For protein detection, blots were probed with either goat anti-human IgE ( $\epsilon$  chain-specific) or goat anti-human IgG ( $\gamma$  chain-specific) conjugated to alkaline phosphatase (KPL, Gaithersburg, Maryland). Color development was performed with an alkaline phosphatase conjugated substrate kit (BIO-RAD, Hercules, California).

**Binding analysis.** Human FcR binding of the purified GE2 protein was tested by binding to Fc $\epsilon$ RI-transfected CHO3D10 cells and HMC-1 cells expressing Fc $\gamma$ RII and then analyzed by flow cytometry (FACSCalibur) using the FITC-conjugated anti-human IgE and anti-human IgG1 reagents (Biosource, Camarillo, California).

**Histamine release.** Acid-stripped Percoll-enriched human blood basophils were sensitized with chimeric human anti-NIP IgE (10  $\mu$ g/ml) at 37 °C in a 5% CO<sub>2</sub> incubator and 1 h later, challenged with 50 ng of NIP-BSA (ref. 19). Histamine release was measured in the supernatants 30 min later. GE2 or control human myeloma IgE was added at various doses and times to test the effects on histamine release.

**Measurement of Syk phosphorylation.** NIP-sensitized basophils were incubated with or without GE2 (10  $\mu$ g/ml), washed and challenged for 2, 5 or 15 min with 50 ng/ml NIP-BSA. Treated or control NIP-IgE sensitized basophils were lysed in 400  $\mu$ l of 50 mM Tris (pH 7.5), 150 mM NaCl, 1% Brij, 1 mM sodium orthovanadate and 1  $\mu$ g/ml each of antipain, leupeptin, aprotinin and phenylmethanesulfonyl fluoride (PMSF) and incubated for 10 min on ice. Immune complexes were generated by incubating clarified supernatants with anti-Syk pre-adsorbed to protein A-Sepharose beads (Pharmacia, Uppsala, Sweden). Proteins were separated by SDS-PAGE, transferred to nitrocellulose and phosphoproteins identified by anti-phosphotyrosine immunoblotting using enhanced chemiluminescence detection reagents (ECL, Amersham, Piscataway, New York). After probing with anti-phosphotyrosine antibody, blots were stripped for 30 min with 100 mM 2-mercaptoethanol, 2% SDS (w:v), and 0.5 M Tris-HCl buffer (pH 6.8) at 50 °C, and then reprobed with anti-Syk antibody (1  $\mu$ /ml).

**Passive cutaneous anaphylaxis.** Transgenic mice expressing the human Fc $\epsilon$ RI $\alpha$  chain and with the murine Fc $\epsilon$ RI $\alpha$  chain knocked out<sup>20</sup> were primed intradermally with 250 ng of NP-specific recombinant human IgE (ref. 21) in 50  $\mu$ l saline. Individual sites were injected with saline, GE2 or IgE myeloma protein simultaneously. 4 h later mice were then given an intravenous challenge with 1.5 mg/ml of NP-BSA plus 1% Evans blue in 300  $\mu$ l saline solution. Cutaneous anaphylaxis was assessed visually by the blue dye leakage from blood vessels into the skin.

## Acknowledgements

We thank S.L. Morrison and R. Trinh for technical assistance and providing some experimental materials. We also thank Jean-Pierre Kinet for providing the transgenic mice expressing the

human FcεRIα. We are grateful to M. Lipscomb and J. Oliver from the UNM Asthma SCOR programs. This study was supported by NIH grant (AI-15251) to A.S. C.L.K. was supported by an American Lung Association-funded UNM Asthma Research Center grant, an Interest Section grant from the AAAAI and a Fellowship from the Parker B. Francis Foundation.

### Author notes

Daocheng Zhu and Christopher L. Kepley: D.Z. and C.L.K. contributed equally to this study.

### Affiliations

*Division of Clinical Immunology/Allergy, Department of Medicine, The Hart and Louise Lyon Laboratory, University of California Los Angeles School of Medicine, Los Angeles, California, USA: Daocheng Zhu, Min Zhang, Ke Zhang & Andrew Saxon*

*Department of Pathology, University of New Mexico Health Sciences Center, Albuquerque, New Mexico, USA: Christopher L. Kepley*

### References

1. Ott, V.L. & Cambier, J.C. Activating and inhibitory signaling in mast cells: New opportunities for therapeutic intervention? *J. Allergy Clin. Immunol.* **106**, 429–440 (2000).
2. Ravetch, J.V. Fc receptors. *Curr. Opin. Immunol.* **9**, 121–125 (1997).
3. Daeron, M. et al. The same tyrosine-based inhibition motif, in the intracytoplasmic domain of FcγRIIB, regulates negatively BCR-, TCR-, and FcR-dependent cell activation. *Immunity* **3**, 635–646 (1995).
4. Daeron, M., Malbec, O., Latour, S., Arock, M. & Fridman, W.H. Regulation of high-affinity IgE receptor-mediated mast cell activation by murine low-affinity IgG receptors. *J. Clin. Invest.* **95**, 577–585 (1995).
5. Oliver, J.M., Kepley, C.L., Ortega, E. & Wilson, B.S. Immunologically mediated signaling in basophils and mast cells: Finding therapeutic targets for allergic diseases in the human FcεRI signaling pathway. *Immunopharmacology* **48**, 269–281 (2000).
6. Daeron, M. Fc receptor biology. *Annu. Rev. Immunol.* **15**, 203–234 (1997).
7. Daeron, M. Building up the family of ITIM-bearing negative co-receptors. *Immunol. Lett.* **54**, 73–76 (1996).
8. Ono, M., Bolland, S., Tempst, P. & Ravetch, J.V. Role of the inositol phosphatase SHIP in negative regulation of the immune system by the receptor FcγRIIB. *Nature* **383**, 263–266 (1996).

9. Fong, D.C. et al. Selective *in vivo* recruitment of the phosphatidylinositol phosphatase SHIP by phosphorylated Fc $\gamma$ R IIB during negative regulation of IgE-dependent mouse mast cell activation. *Immunol. Lett.* **54**, 83–91 (1996).
10. Daeron, M. Negative regulation of mast cell activation by receptors for IgG. *Int. Arch. Allergy Immunol.* **113**, 138–141 (1997).
11. Malbec, O. et al. Fc $\epsilon$  Receptor I-associated lyn-dependent phosphorylation of Fc $\gamma$  Receptor IIB during negative regulation of mast cell activation. *J. Immunol.* **160**, 1647–1658 (1998).
12. Ravetch, J.V. & Lanier, L.L. Immune inhibitory receptors. *Science* **290**, 84–89 (2000).
13. Takai, T., Ono, M., Hikida, M., Ohmori, H. & Ravetch, J.V. Augmented humoral and anaphylactic responses in Fc $\gamma$ R II-deficient mice. *Nature* **379**, 346–349 (1996).
14. Huston, J.S. et al. Protein engineering of antibody binding site: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in *Escherichia coli*. *Proc. Natl. Acad. Sci. USA* **85**, 5879–5883 (1988).
15. Helm, B. et al. The mast cell binding site on human immunoglobulin E. *Nature* **331**, 180–183 (1988).
16. Hulett, M.D., Witort, E., Brinkworth, R.I., McKenzie, I.F. & Hogarth, P.M. Identification of the IgG binding site of the human low affinity receptor for IgG Fc gamma RII. *J. Biol. Chem.* **269**, 15287–15293 (1994).
17. Hendershot, L.M. & Kearney, J.F. A role for human heavy binding protein in the developmental regulation of immunoglobulin transport. *Mol. Immunol.* **25**, 585–593 (1988).
18. Wedi, B., Lewrick, H., Butterfield, J.H. & Kapp, A. Human HMC-1 mast cells exclusively express the Fc $\gamma$ R II subtype of IgG receptor. *Arch. Dermatol. Res.* **289**, 21–27 (1996).
19. Kepley, C.L. et al. Negative regulation of Fc $\epsilon$ RI signaling by Fc $\gamma$ R II costimulation in human blood basophils. *J. Allergy Clin. Immunol.* **106**, 337–348 (2000).
20. Dombrowicz, D. et al. Anaphylaxis mediated through a humanized high affinity IgE receptor. *J. Immunol.* **157**, 1645–1651 (1996).
21. Fung-Leung, W.P. et al. Transgenic mice expressing the human high-affinity immunoglobulin (Ig) E receptor  $\alpha$  chain respond to human IgE in mast cell degranulation and in allergic reactions. *J. Exp. Med.* **183**, 49–56 (1996).